公开(公告)号：EP3148532B1

公开(公告)日：2021-03-03

申请号：EP15799889.9

申请日：2015-05-27

发明人： ORWAR, Owe ,  SRINIVASA, Sreesha ,  MISHRA, Prabha

IPC分类号： A61K31/4025 ,  A61K31/4412 ,  A61K31/425 ,  A61K31/513 ,  A61K31/28 ,  A61P35/00 ,  A61K45/06 ,  A61K31/41 ,  A61K31/519 ,  A61K31/553 ,  A61K31/7135 ,  A61K33/36

公开(公告)号：EP3107901B1

公开(公告)日：2020-04-01

申请号：EP15711292.1

申请日：2015-02-18

申请人： Piramal Enterprises Limited

发明人： KUMAR, Sanjay ,  SHARMA, Rajiv ,  HALDER, Somnath ,  SAWARGAVE, Sangameshwar Prabhakar ,  DEORE, Vijaykumar Bhagwan

IPC分类号： C07C59/72 ,  C07C59/86 ,  C07D213/30 ,  C07D213/57 ,  C07D213/65 ,  C07D213/64 ,  C07D221/04 ,  C07D239/26 ,  C07D277/24 ,  C07D277/60 ,  C07D277/66 ,  C07D285/12 ,  C07D305/06 ,  C07D305/08 ,  C07D307/80 ,  C07D333/16 ,  C07D333/24 ,  C07D333/56 ,  A61K31/192 ,  A61P3/10

公开(公告)号：EP3436426A1

公开(公告)日：2019-02-06

申请号：EP17773401.9

申请日：2017-03-28

申请人： Piramal Enterprises Limited

发明人： GHARPURE, Milind ,  JAGTAP, Ashutosh ,  RAUT, Changdev ,  KANSAGARA, Nainesh ,  KRISHNAPILLAI, Jaisankar ,  MANOHARAN, Nirmal Kumar ,  PATIL, Navnath

IPC分类号： C07C227/32 ,  C07C229/36 ,  C07B53/00 ,  C07F15/04 ,  C07D317/54 ,  C07C227/40

公开(公告)号：EP3383829A1

公开(公告)日：2018-10-10

申请号：EP16870086.2

申请日：2016-11-30

申请人： Piramal Enterprises Limited

发明人： GHARPURE, Milind ,  LADKAT, Prashant ,  SHINDE, Navnath ,  JAGTAP, Ashutosh

IPC分类号： C07B63/00 ,  C07B47/00

摘要： The present invention relates to a novel process for the preparation of intermediate of fosaprepitant dimeglumine. The present invention particularly relates to a process for the preparation of fosaprepitant dibenzyl ester, an intermediate of fosaprepitant dimeglumine, which is simple, easy to handle on commercial scale and efficient.

公开(公告)号：EP3160981A1

公开(公告)日：2017-05-03

申请号：EP15811513.9

申请日：2015-06-24

申请人： Piramal Enterprises Limited

发明人： SHARMA, Rajiv ,  BORHADE, Namdev Narayan ,  CHAKOR, Narayan Subhash ,  MISTRY, Hitesh Devchandbhai

IPC分类号： C07J71/00 ,  A61K31/58 ,  A61P37/00 ,  A61P35/00

CPC分类号： A61K31/58 ,  A61K45/06 ,  C07J63/008 ,  C07J71/0047 ,  C07J71/0063

摘要： The present invention discloses fused triterpene compounds, represented by the compounds of Formula I (as described herein), processes for their preparation, pharmaceutical compositions comprising the said compounds, their use as retinoid-related orphan receptors gamma (RORγ) modulators and/or interleukin-17 (IL-17) inhibitors and methods for their use in the treatment of a disease or a disorder mediated by RORγ and/or IL-17.

摘要翻译： 本发明公开了由式I化合物表示的融合三萜化合物（如本文所述），其制备方法，包含所述化合物的药物组合物，其作为类维生素A相关孤儿受体γ（RORγ）调节剂和/或白细胞介素 -17（IL-17）抑制剂及其用于治疗由RORγ和/或IL-17介导的疾病或病症的方法。

公开(公告)号：EP3062803A1

公开(公告)日：2016-09-07

申请号：EP14857459.3

申请日：2014-10-28

申请人： Piramal Enterprises Limited

发明人： PIRAMAL, Swati, Ajay ,  SUTHAR, Ashish, Chandrakant ,  SHELAR, Rahul, Ramesh

IPC分类号： A61K36/42 ,  A61P3/10

CPC分类号： A61K36/42 ,  A61K31/7072 ,  A61K31/7076 ,  A61K2236/13 ,  A61K2236/15 ,  A61K2236/31

摘要： The present invention relates to a standardised extract of Momordica Charantia containing one or more nitrogen containing heterocyclic compounds as the bioactive markers and a process for the preparation thereof. The present invention also relates to a composition comprising the standardised extract of Momordica Charantia containing one or more nitrogen containing heterocyclic compounds as the bioactive markers. The present invention also relates to use of the standardised extract of Momordica Charantia or the composition containing the said standardised extract for the treatment of metabolic disorders such as diabetes.

摘要翻译： 本发明涉及一种苦瓜含有一种或多种含氮杂环化合物作为生物活性标记和一种用于其制备的标准化提取物。 瓦本发明因此涉及包括苦瓜含有一种或多种含氮杂环化合物作为生物活性标记的标准化提取物的组合物。 因此，本发明涉及使用苦瓜或含有代谢紊乱的治疗中，所述标准化提取物的组合物的标准化提取物：如糖尿病。

公开(公告)号：EP2427188B1

公开(公告)日：2016-08-10

申请号：EP10724898.1

申请日：2010-05-03

申请人： Piramal Enterprises Limited

发明人： RATHOS, Maggie Joyce ,  JOSHI, Kalpana Sanjay ,  HEBBAR, Nikhil Krishnamurthy ,  SHARMA, Somesh

IPC分类号： A61K31/4025 ,  A61K31/00 ,  A61P35/02

CPC分类号： A61K31/00 ,  A61K31/4025 ,  A61K2300/00

公开(公告)号：EP2723449A2

公开(公告)日：2014-04-30

申请号：EP12738614.2

申请日：2012-06-22

申请人： Piramal Enterprises Limited

发明人： PIRAMAL, Swati Ajay ,  PADIGARU, Muralidhara ,  AGARWAL, Veena R ,  DESHPANDE, Gandhali Ashwin

IPC分类号： A61P35/00 ,  A61K31/4025

CPC分类号： A61K31/4025 ,  A61K45/06 ,  C07D405/04

摘要： The present invention relates to the pyrrolidine substituted with flavone derivatives, represented by the compounds of Formula (I) or a pharmaceutically acceptable salt, a solvate, a stereoisomer or a diastereoisomer thereof for use in the treatment of cancers associated with human papillomavirus. The present invention also relates to the pharmaceutical compositions containing the compounds of Formula (I) for the treatment of cancers associated with human papillomavirus.

公开(公告)号：EP2714031A1

公开(公告)日：2014-04-09

申请号：EP12738184.6

申请日：2012-05-30

申请人： Piramal Enterprises Limited

发明人： AGARWAL, Veena ,  BALAKRISHNAN, Arun ,  PERIYASAMY, Giridharan

IPC分类号： A61K31/337 ,  A61K31/4025 ,  A61K31/4412 ,  A61K31/513 ,  A61K31/517 ,  A61K33/24 ,  A61P35/00 ,  A61K39/395

CPC分类号： A61K31/4025 ,  A61K31/282 ,  A61K31/337 ,  A61K31/44 ,  A61K31/513 ,  A61K31/517 ,  A61K33/24 ,  A61K39/39558 ,  A61K2300/00

摘要： or a pharmaceutically acceptable salt thereof and one or more antineoplastic agents selected from sorafenib, lapatinib, erlotinib, cisplatin, 5-fluorouracil, docetaxel or cetuximab or a pharmaceutically acceptable salt thereof. The said pharmaceutical combination exhibits synergy when used in the treatment of squamous cell carcinoma of head and neck (SCCHN). The invention also relates to a pharmaceutical composition comprising the said combination and a method for the treatment of squamous cell carcinoma of head and neck (SCCHN), using a therapeutically effective amount of said combination.

摘要翻译： 本发明涉及一种用于在鳞状细胞癌的治疗中使用的药物组合，其包含由式（I）的化合物中选择的CDK抑制剂; 或其药学上可接受的盐和选自索拉非尼，拉帕替尼，厄洛替尼，顺铂，5-氟尿嘧啶，多西他赛或西妥昔单抗或其可药用的盐中选择的一种或多种抗肿瘤剂。 所述药物组合显示协同作用当在头部和颈部（SCCHN）的鳞状细胞癌的治疗中使用。 因此，本发明涉及包含所述组合以及用于治疗头部和颈部（SCCHN）的鳞状细胞癌，使用治疗有效量的所述组合的方法的药物组合物。

公开(公告)号：EP2640380A1

公开(公告)日：2013-09-25

申请号：EP11805197.8

申请日：2011-11-18

申请人： Piramal Enterprises Limited

发明人： RATHOS, Maggie, Joyce ,  JOSHI, Kalpana, Sanjay

IPC分类号： A61K31/4025 ,  A61K31/337 ,  A61P35/00

CPC分类号： A61K31/4025 ,  A61K31/337 ,  A61K31/352

摘要： The present invention relates to a pharmaceutical combination comprising paclitaxel, or its pharmaceutically acceptable salt; and at least one cyclin dependent kinase (CDK) inhibitor represented by a compound of formula I (as described herein) or a pharmaceutically acceptable salt thereof, for use in the treatment of triple negative breast cancer (TNBC). The present invention relates to a method for the treatment of breast cancer, particularly triple negative breast cancer, by administration to a patient in need thereof, a therapeutically effective amount of a pharmaceutical combination comprising a cytotoxic antineoplastic agent, paclitaxel, and at least one cyclin dependent kinase (CDK) inhibitor; wherein said combination on administration exhibits synergistic effects.